Stockscreener 앱 받기
37.36
7.80%
-3.16
시간 외 거래:
37.95
0.59
+1.58%
전일 마감가:
$40.52
열려 있는:
$40.44
하루 거래량:
3.21M
Relative Volume:
1.95
시가총액:
$4.42B
수익:
$18.47M
순이익/손실:
$-589.53M
주가수익비율:
-7.1027
EPS:
-5.26
순현금흐름:
$-399.80M
1주 성능:
-13.50%
1개월 성능:
-14.49%
6개월 성능:
-34.09%
1년 성능:
-46.00%
1일 변동 폭
$36.89
$40.62
1주일 범위
$36.89
$43.69
52주 변동 폭
$36.89
$75.71
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
37.36 | 4.42B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Cytokinetics director Robert Harrington sells shares worth $17,743 - Investing.com India
Cytokinetics stock holds $78 target from JMP amid trial results By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains overweight on Cytokinetics stock By Investing.com - Investing.com Canada
Why These Two Biotech Stocks Just Diverged - Investor's Business Daily
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' - Investopedia
CYTK Gains as EWTX Data and Fundraising Impact Stock Movement - GuruFocus
Raymond James maintains Cytokinetics stock with $81 target By Investing.com - Investing.com UK
Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals
Cytokinetics stock rises on Edgewise data for lead drug (EWTX) - Seeking Alpha
Cytokinetics CEO compensation jumps 64%, thanks in large part to stock awardsSan Francisco Business Times - The Business Journals
Cytokinetics CEO Makes Major Stock Move! - TipRanks
Former Gilead legal star departs Cytokinetics as crucial FDA ruling approachesSan Francisco Business Times - The Business Journals
Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Cytokinetics Leadership Takes Center Stage at Elite Needham Healthcare Conference - Stock Titan
Cytokinetics stock hits 52-week low at $40.49 amid market challenges - Investing.com UK
Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy - Insider Monkey
Cytokinetics, Madrigal, and BridgeBio Emerge as Potential Pharma Takeover Targets - GuruFocus
Cytokinetics Announces Data From Phase 1 Study of CK-4021586 - MarketScreener
Is Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last? - MSN
Cytokinetics Launches EARTH-HCM: An Interactive Tool for Understanding Hypertrophic Cardiomyopathy and Improving Access to Care - Nasdaq
Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community - The Manila Times
Groundbreaking Healthcare Tool Unlocks Insights from 65,000 Pharmacies' HCM Data - Stock Titan
Cytokinetics EVP Malik sells $87,160 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Malik sells $87,160 in stock - Investing.com
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics announces inducement grants under Nasdaq listing rule 5635(C)(4) -March 18, 2025 at 04:15 pm EDT - MarketScreener
Cytokinetics Strengthens Workforce: 13 New Hires Secure Strategic Equity Awards - StockTitan
H.C. Wainwright maintains Buy on Cytokinetics, $120 target By Investing.com - Investing.com UK
Cytokinetics Executives Engage in Multiple Stock Transactions - TradingView
Cytokinetics Incorporated: Aficamten's Differentiated Profile and Market Potential Is Powering Our Hopefulness! - Smartkarma
UBS Lowers Price Target on Cytokinetics to $47 From $61, Maintains Neutral Rating -March 17, 2025 at 11:27 am EDT - Marketscreener.com
Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo - The Manila Times
Cytokinetics Announces Five Presentations at the American College of Cardiology Annual ... - NRToday.com
Breakthrough: Cytokinetics HCM Drug Delivers Powerful 72-Week Heart Improvement Data - Stock Titan
Cytokinetics’ EVP sells $4,500 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $4,500 in stock By Investing.com - Investing.com UK
Cytokinetics’ EVP sells $4,500 in stock - Investing.com India
Cytokinetics EVP Callos Andrew sells shares for $1.17 million By Investing.com - Investing.com South Africa
Cytokinetics EVP Callos Andrew sells shares for $1.17 million - Investing.com
Charles Schwab Investment Management Inc. Raises Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics at Barclays Healthcare Conference: Strategic Launch Plans By Investing.com - Investing.com UK
Cytokinetics at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com Australia
Citi maintains Cytokinetics stock Buy rating, $86 target By Investing.com - Investing.com Canada
Promising Progress and Positive Outlook for Cytokinetics’ Aficamten in oHCM Treatment - TipRanks
RBC Capital stays bullish on Cytokinetics on lack of AdCom in aficamten view - TipRanks
Cytokinetics regulatory update ‘incrementally positive,’ says Morgan Stanley - TipRanks
Why Have Cytokinetics Stocks Plummeted? - TipRanks
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):